Install
Research and Innovation
What the labs are producing.
- 23 Tracked terms
- Last 30 days Feed window
What this topic collects on
An article joins this feed when it matches these terms. Each one is also a search of its own.
Related topics
Latest in Research and Innovation
Bristol Myers' Phase 3 Trial Of Admilparant In Idiopathic Pulmonary Fibrosis Met Primary Endpoint
2+ day, 20+ hour ago (173+ words) Bristol Myers Squibb (BMY), a biopharmaceutical company, announced Monday the topline results from its pivotal Phase 3 ALOFT-IPF trial evaluating admilparant in adults with idiopathic pulmonary fibrosis (IPF). Admilparant is a potential first-in-class, orally administered lysophosphatidic acid receptor 1 (LPA1) antagonist. The trial…...
Bristol Myers falls 3% despite positive cancer drug trial results
2+ day, 16+ hour ago (202+ words) Bristol-Myers Squibb Co (NYSE:BMY, XETRA:RM, OTC:BMYMP) shares fell 3% to $57.39 after positive results from a late-stage trial of an experimental cancer treatment raised questions about the market's reaction to the announcement. RYZ101 is a targeted radiopharmaceutical therapy developed by…...
Bristol Myers Squibb Says RayzeBio's Phase 3 Study for RYZ101 Meets Primary Endpoint
2+ day, 22+ hour ago (187+ words) Bristol Myers Squibb (BMY) said Monday that an interim analysis of a phase 3 trial evaluating RayzeBio's radiopharmaceutical therapy RYZ101 met its primary endpoint. Bristol Myers... Oops, something went wrong U.S. markets close in 3h 40m Bristol Myers Squibb Says RayzeBio's Phase 3 Study for RYZ101 Meets…...
Bristol down as Street reacts to admilparant results in IPF
2+ day, 17+ hour ago (60+ words) Bristol Myers slips after mixed phase 3 admilparant IPF results; analysts weigh dose-response concerns and approval odds. Read more here. After opening Monday's trading session initially higher, Bristol Myers Squibb (BMY) shares are now down ~3% as the Street more fully digests…...
Bristol Myers dips on ‘confounding’ lung drug results
2+ day, 10+ hour ago (360+ words) Only the lower of two tested doses of the idiopathic pulmonary fibrosis drug admilparant met the trial’s main objective, adding to analyst questions about the therapy’s prospects. Admilparant is the furthest along among a class of idiopathic pulmonary fibrosis, or…...
Bristol Myers Squibb Announces Positive Topline Results from the Interim Analysis of Phase 3 ACTION-1 for RYZ101, RayzeBio’s Radiopharmaceutical Therapy, in Patients with GEP-NETs
2+ day, 15+ hour ago (55+ words) Individuals currently enrolled will continue to receive care consistent with the study protocol, and participants will be followed for overall survival. About Bristol Myers Squibb: Transforming Patients’ Lives Through Science KEYWORD: NEW JERSEY UNITED STATES NORTH AMERICA SOURCE: Bristol Myers…...
New Bristol spinout turns moth-wing science into revolutionary acoustic material
1+ week, 2+ day ago (618+ words) Press release issued: 6 October 2026 Inspired by the microscopic structures found on moth wings, the technology has the potential to deliver sound absorption performance while being up to ten times thinner than conventional materials, with potential applications across construction, transport, aerospace,…...
Bristol-Myers' Protocol Changes Add Risk, Keep Admilparant on Track, UBS Says
2+ week, 22+ hour ago (53+ words) Bristol-Myers Squibb's (BMY) protocol updates to the phase 3 long-term extension study of admilparant in idiopathic pulmonary fibrosis introduce some added risk while maintaining... Oops, something went wrong Bristol-Myers' Protocol Changes Add Risk, Keep Admilparant on Track, UBS Says Bristol-Myers Squibb's…...
University of Bristol???s showpiece new innovation zone welcomes first ambitious firms
3+ week, 6+ day ago (87+ words) Eight pioneering firms spanning sensor technology, AI, health technology, intellectual property and higher education consulting have become the first businesses to take up residency in a dedicated... University of Bristol’s showpiece new innovation zone welcomes first ambitious firms More from…...